Skip to main content
NCBI home page
Journal of Cancer logoLink to Journal of Cancer
. 2018 Oct 18;9(21):4072–4086. doi: 10.7150/jca.26399

Cytoplasmic SQSTM1/ P62 Accumulation Predicates a Poor Prognosis in Patients with Malignant Tumor

Linhai Zhu 1,*, Yiqing Wang 1,*, Jing He 2,*, Jie Tang 1, Wang Lv 1, Jian Hu 1,✉
PMCID: PMC6218778  PMID: 30410612

Abstract

Aims: SQSTM1/p62, as an autophagy marker, is a key molecule involved in the autophagy process. Recent studies have demonstrated that p62 has a close relationship with tumorigenesis and progression, but the impact of p62 on patients' survival has not been comprehensively understood. Therefore, we conducted this study to assess the expression level of p62 in tumor cells and the prognostic role of p62 expression in various malignant tumors.

Methods: We searched PubMed, PubMed Central (PMC), Embase, Ovid and Web of Science databases and identified 30 eligible studies containing 14,072 patients to include in the meta-analysis. The p62 mRNA and protein expression profiles in various tumor tissues and normal tissues were presented according to the Human Protein Atlas (HPA) and the Gene Expression Profiling Interactive Analysis (GEPIA). We also tested the association between p62 mRNA level and patients' survival based on the Cancer Genome Atlas (TCGA) and the Human Protein Atlas (HPA) databases.

Results: The expression levels of p62 mRNA and protein varied in different tissues. The p62 proteins were elevated and mainly located in the cytoplasm in some types of tumor compared with the normal tissues. The pooled results indicated that p62 overexpression in tumor tissues was associated with a worse prognosis. In the subgroup analysis, a significant relationship was observed between cytoplasmic p62 accumulation and both overall survival (HR 1.53, 95% CI: 1.03-2.27, P < 0.05) and disease-specific survival (HR 1.60, 95% CI: 1.15-2.24, P < 0.01). The relationship between p62 and worse survival was more evident in early stage tumors. P62 mRNA expression had no significant effect on the patient's survival except of liver cancer.

Conclusions: The findings of this meta-analysis highlight the role of p62 as a useful prognostic biomarker for some types of tumor according to different clinicopathologic features, which may contribute to the selection of effective treatment methods for different malignant tumors.

Keywords: SQSTM1/p62, malignant tumor, prognosis

Introduction

Malignant tumors have been a major cause of death in economically developed countries and are expected to grow across the world because of the aging of the population 1. It is estimated that 14.1 million new cancer cases and 8.2 million cancer deaths occurred in 2012 worldwide 1. Despite significant advances in diagnosis and therapy, the prognosis of most malignant tumors is still unfavorable. The effective treatment of cancer relies heavily on better understanding the mechanism of the carcinogenesis, and discovering suitable tumor biomarkers to indicate the exact individualized therapy.

Macroautophagy (hereinafter referred to as autophagy) is a conserved programmed cell survival mechanism which refers to a basic catabolic process that delivers damaged intracellular organelles or proteins to the lysosomes for subsequent degradation and recycling of substrates in order to maintain cellular homeostasis 2. The dysregulation of autophagy is involved in a broad spectrum of diseases, such as cancer, heart diseases and neurodegeneration diseases 3-5. We can speculate that autophagy might play a paradoxical role in cancer according to its basic function. In early stage, autophagy may serve as a tumor suppressor by eliminating the defective organelles or toxic proteins, which may produce free radicals to cause genomic instability 6. But in late stage, autophagy allows cancer cells to survive, invade, metastasize and evade cell death by eliminating deleterious cellular components and recycling nutrients in response to various stresses 7. Exploiting autophagy for predictive biomarkers and anti-cancer therapeutic targets has become a field gaining ever increasing attention. However, until now, the exact role of autophagy in cancer is still unclear.

Mammalian sequestosome 1 (SQSTM1, hereinafter referred to as p62), is identified as an adaptor protein and functions in assembling protein complexes by several binding motifs 8. Recently, p62 is considered as an indicator of functional basal autophagy 9. P62 localizes at the autophagosomal membranes and works as an autophagy receptor through interacting with microtubule-associated protein 1 light chain 3 B (LC3B) and ubiquitinated cargoes 10. During the process of autophagy flux, p62 itself is constantly degraded with the ubiquitinated substrates 11. Thus, reduced p62 reflect active autophagy and conversely impaired autophagy can be indicated by an associated accumulation of p62 12. Exploring the role of p62 in cancer can promote a better understanding of the relationship between autophagy and cancer. However, there is still a lot of confusion about the clinical significance of p62 in most malignant tumors nowadays.

This study is conducted to investigate the differences of p62 expression level between tumor tissues and normal tissues, and the prognostic value of p62 in certain types of tumor. Ultimately, our results indicated that p62 protein elevated and mainly located in the cytoplasm in tumor cells in comparison with that in normal cells, and the cytoplasmic p62 accumulation predicated a poor prognosis in some types of malignant tumor.

Materials and methods

Search strategy

This meta-analysis was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA) 13. PubMed, PubMed Central (PMC), Embase, Ovid and Web of Science databases were used for literature search. The following keywords were employed: “sequestosome 1 or SQSTM1 or p62”, “cancer or tumor or carcinoma” and “prognosis or outcome or survival”. The latest search was carried out on July 1, 2018. We also consulted the references of identified articles for all relevant studies.

Selection criteria

Eligible study was enrolled in this meta-analysis in line with the following criteria: (1) p62 expression was detected in tumor tissues; (2) the outcomes of interest were in terms of overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), recurrence-free survival (RFS), metastasis-free survival (MFS) or disease-specific survival (DSS); and (3) sufficient data to estimate the hazard ratio (HR) and its 95% confidence intervals (CI) according to the p62 expression was reported. When the same patient cohort was reported in more than one study, the complete or the most recent one was selected. The exclusion criteria were following: (1) Articles without adequate survival data for extracting HRs and corresponding 95% CIs; (2) Articles in non-English; and (3) Reviews, summary of meeting, case reports, letters to the editor and non-human trials. Titles and abstracts of the identified articles were screened, and then comprehensive evaluation was carried out by viewing the full text carefully. Any disagreement was resolved via consensus.

Data extraction and quality assessment

Two reviewers independently extracted relevant information from all eligible studies. The following items were extracted: first author's name, publication year, country of origin, study recruitment years, period of follow-up, tumor type, staining pattern, age at the time of diagnosis, patients' gender, tumor stage, sample size, detection method, cutoff value and assessments of outcomes. HR and the corresponding 95% CI of the high p62 expression group versus the low one for OS, PFS, DFS or DSS were also collected as applicable. If the survival outcomes were presented by both univariate and multivariate analyses, we chose the result of multivariate analysis. For studies in which HRs was not provided explicitly, we extracted the survival estimates from the original data or Kaplan-Meier curves using the Tierney's methods 14. The level of p62 expression in tumor tissues and normal tissues was also extracted from the articles.

The quality of each study was assessed according to the Newcastle-Ottawa Scale (NOS) 15. The NOS evaluates a study in three domains including selection of participants, comparability of study groups and the ascertainment of outcomes with the score ranged from 0 to 9. A study achieving a score of six or more was deemed as a high quality one.

P62 mRNA and protein expression profiles in various tumor tissues and normal tissues according to the Human Protein Atlas (HPA) and the Gene Expression Profiling Interactive Analysis (GEPIA)

The p62 mRNA and protein expression in different normal human tissues were generated in the HPA project (https://www.proteinatlas.org). RNA-seq results are reported as Fragments per Kilo-base of exon per Million reads (FPKM). The score of protein expression is based on the staining intensity and fraction of stained cells and describes the level of antibody staining observed in the annotated cell types as not detected, low, medium or high.

The p62 mRNA expression profile across all tumor samples and paired normal tissues were generated in GEPIA (http://gepia.cancer-pku.cn/index.html). The RNA-seq results are reported as number of transcripts per million (TPM).

P62 mRNA expression and patient survival in various tumors according to the Cancer Genome Atlas (TCGA) and the Human Protein Atlas (HPA)

The correlation between p62 expression at the mRNA level and patients survival in various tumors was examined based on the data from TCGA database (https://cancergenome.nih.gov/). The FPKMs (number Fragments per Kilo-base of exon per Million reads) were used for quantification of p62 mRNA level.

The prognosis of patients grouped by p62 mRNA expression was examined by Kaplan-Meier survival estimators, and the survival outcomes of the two groups were compared by log-rank tests. The median and maximally separated Kaplan-Meier curves are drew by the HPA. The log-rank P values less than 0.001 in maximally separated Kaplan-Meier analysis were considered significant statistically.

Statistical analysis

The overexpression of p62 was defined according to the cutoff values provided by the original studies. Pooled HRs and 95% CIs were used to assess the relationship between p62 overexpression and prognosis of patients. Heterogeneity of HRs across the studies was evaluated using I-squared statistics 16. I2 > 50% indicated a statistically significant heterogeneity, which allowed the use of a random-effect model. Otherwise, a fixed-effect model was applied. To explore the possible sources of heterogeneity and further investigate the relationship between the p62 overexpression and survival of patients with different clinicopathological features, subgroup analyses were adopted. We also performed sensitivity analyses by omission of each single study to evaluate stability of the results. Potential publication bias was assessed by the Begg's funnel plot and Egger's test. STATA software version 12.0 (Stata Corporation, TX, USA) was utilized in this meta-analysis. In the process of meta-analysis, P < 0.05 was considered statistically significant.

Results

Study characteristics

According to the searching strategy described in the materials and methods, 9,655 articles were initially retrieved. Among them, 9,324 were excluded by screening the titles and abstracts, and then, 296 were excluded by the full-texts. At last, 30 articles met the inclusion criteria and were included into the meta-analysis after further evaluation. In addition, 5 studies reporting mean survival time of cancer patients were listed separately. The flow chart of the study search and selection process is reported in Figure 1.

Figure 1.

Figure 1

Open in a new tab

Flow diagram of the study selection process.

The main features of the 30 included studies are summarized in Table 1. A total of 14,072 patients from China, Germany, Japan, Korea, Norway, Switzerland, UK, and USA were diagnosed with various tumors, including breast cancer, colorectal cancer, endometrial cancer, epithelial ovarian cancer, esophageal cancer, gastric cancer, glioma, hepatocellular carcinoma, hypopharyngeal squamous cell carcinoma, lacrimal gland adenoid cystic carcinoma, melanoma, non-small cell lung cancer (NSCLC), oral squamous cell carcinoma, pancreatic cancer, prostate cancer, soft tissue sarcoma, thyroid cancer, and nasopharyngeal cancer. All of the studies were designed retrospectively and the year published ranged from 2007-2018. We selected OS, PFS and DSS as the main survival outcomes of all eligible studies for our meta-analysis. The quality of the 30 eligible studies enrolled in our meta-analysis was evaluated according to the NOS. The quality of the eligible studies ranged from 5 to 7, with a mean of 6.97. The main characteristics of another 5 studies reporting mean survival time were listed in Table 3. Four studies represented the survival time as mean with 95% CI, and 1 study reported as mean ± standard deviation (SD). The cut-off values of p62 varied in different studies.

Table 1.

Main characteristics of studies included in the meta-analysis

Author Year Country Study recruitment years Follow-up time (months) Tumor type Staining pattern Age (years),mean Gender (M/F) Stage Sample size (n) Detection method Cutoff Outcomes NOS score
Yang Q 33 2018 China NA Median 50.86, range (12.93-72.23) Nasopharyngeal Whole cell 73 (≤50); 43(>50) 85/31 I-II 13; III-IV 103 116 IHC (Santa Cruz) Score>3 MFS; OS 6
Terabe T 34 2017 Japan 1997-2009 NA Oral Whole cell 38 (≤65); 33(>65) 40/31 I-II 37; III-IV 34 71 IHC (Abcam) >1% RFS; DSS 6
Xu LZ 35 2017 China 1999-2008 NA Breast cancer Whole cell Median 48 Female 369 I 76, II 173, III 117, IV 2 369 IHC (NA) NA OS, DFS 8
Arai A 36 2017 Japan 1997-2008 Max 120 Hypopharyngeal Whole cell Mean 65.1 range (45-81) 47/7 I 4; II 6; III 4; IV 40 54 IHC (MBL) NA DFS 5
Nakayama S 37 2017 Japan 2000-2006 Mean 69.8 (range,2-131) Colorectal Cytoplasm NA 71/47 I-II 63; III-IV 55 118 IHC (MBL) >10% OS 7
Niklaus M 38 2017 Germany 1993-2005 NA Colon Cytoplasm Median 66 range (25-91) 160/132 NA 292 IHC (LabForce) Score≥1 OS 6
Tang DY 39 2016 UK NA NA Melanoma Whole cell NA NA II 75 75 IHC (NA) ≥20% DFS 6
Schlafli AM 40 2016 Switzerland 1988-2008 NA NSCLC Whole cell; cytoplasm; nucleus Median 67 range (39-83) 343/123 I-II 466 IHC (MBL) Score>1 OS; RFS 7
Cao QH 17 2016 China 2002-2006 NA Gastric Whole cell ≥58 174; <58 178 235/117 I 41; II 83; III 192; IV 38 352 IHC (MBL) Score>8 OS 7
Schmitz KJ 41 2016 Germany 1996-1998 Minimum 60 Colorectal Cytoplasm; nucleus Mean 68.19 range (39-91) 66/61 I-II 65; III-IV 62 126 IHC (Santa Cruz) NA DSS 8
Adams O 42 2016 Switzerland 1991-2011 NA Esophageal Whole cell; cytoplasm; nucleus Median 69 range (32-89) 100/16 I 35; II 25; III 51; IV 5 116 IHC (MBL) Score≥1 OS 7
Masuda GO 43 2016 Japan NA Max 60 Gastric Whole cell Median 66 range (21-88) 290/220 I 250; II 76; III 108; IV 76 510 IHC (MBL) >20% OS 8
Jiang X 19 2015 China 1999-2003 120 Prostate Whole cell Mean 69 range (52-85) 111/0 I-II 61; III 50 111 IHC (Enzo) Score≥4 OS 7
Iwadate R 44 2015 Japan 1990-2007 Median 98, range (61-235) Endometrial Cytoplasm NA 0/194 I 143; II 12; III 32; IV 7 194 IHC (Santa Cruz) ≥10% OS 8
Wang X 45 2015 China 2006-2009 Mean 48.5, range (3-96.5) NSCLC Cytoplasm NA 70/34 I-IV 104 IHC (Abcam) Score≥4 OS 7
Burdelski C 46 2015 Germany 1992-2012 Median 36, range (1-241) Prostate Cytoplasm NA 7822/0 pT2-pT4 7822 IHC (Abcam) NA OS 8
Zhao M 47 2015 China 2009-2013 6-60 Glioma Cytoplasm 47.8±16.4 45/30 NA 75 IHC (Santa Cruz) Score≥3 PFS; OS 6
Liu JL 26 2014 China 2003-2008 NA Oral Cytoplasm; nucleus 55.57 ± 11.97 187/8 I-IV 195 IHC (Abcam) Score≥100(cytoplasm);Score≥140(nucleus) OS; DSS; RFS 8
Ellis RA 48 2014 UK NA 84 Melanoma Whole cell NA NA I-IV 121 IHC (NA) ≥20% DFS; DSS; OS 7
Iwadate R 49 2014 Japan 1986-2006 Average 59, range (1-120) Ovarian Cytoplasm 107 ≤50 years, 159 >50 years 0/266 I 150; II 281; III-IV 69 266 IHC (Santa Cruz) ≥10% OS 8
Jin GZ 50 2013 China 1996-2011 Median 33, range (0.3-141) Hepatocellular Whole cell 50.1 ± 10.9 430/70 I 150; II 281; III-IV 69 500 IHC (Sigma) >25% RFS; OS 8
Inui T 51 2013 Japan NA NA Oral Whole cell Median 64.8, range (27-92) 32/22 NA 47 IHC (MBL) >20% DSS 5
Kim SK 52 2013 Korea 2000-2008 NA Breast Whole cell 40.2 ± 12.3 0/204 NA 204 IHC (Abcam) Score≥2 DFS; OS 7
Luo RZ 53 2013 China 2000-2008 Median 112, range (15-145) Breast Whole cell Median 47, range (22-79) 0/163 I-II 121; III 42 163 IHC (Santa Cruz) Score≥2 DFS; OS 7
Park JM 54 2013 USA NA NA Colorectal Whole cell Median 63.5, range (26-81) 99/79 II 32; III 146 178 IHC (MBL) ≥50% OS 7
Chio J 55 2013 Korea 2002-2003 NA Breast Cytoplasm; nucleus 48.6 ± 10.5 0/489 NA 489 IHC (Abcam) Score≥2(cytoplam);>10%(nucleus) DFS; OS 8
Sorbye SW 56 2012 Norway 1973-2006 NA Soft tissue sarcomas Whole cell Mean 55, range (0-89) 81/112 NA 187 IHC (BD) Score≥0.33 DSS 7
Inoue D 57 2012 Japan 1993-1995 Mean 54.2, range (0.5-112) NSCLC Cytoplasm Mean 65.6, range (23-82) 78/31 I 69; II-III 40 109 IHC (Progen) >10% DSS 6
Kim S 58 2012 Korea 2000-2005 59.2±27.9 Breast cancer Cytoplasm; nucleus 47.3±12.1 Female 119 NA 119 IHC (Abcam) Score≥2 OS, DFS 6
Rolland P 59 2007 UK 1987-1998 Median 76 Breast Cytoplasm ≤70 0/523 NA 523 IHC (INC) >5% DSS 8
Open in a new tab

NA, not acquired; M, male; F, female; NSCLC, non-small cell lung cancer; IHC, immunohistochemistry; OS, overall survival; MFS, metastasis free survival; DFS, disease free survival; DSS, disease-specific survival; RFS, relapse free survival; PFS, progression free survival

Table 3.

Main characteristics of 5 studies investigating the relationship between p62 expression and tumor prognosis but not combined into the meta-analysis

Author Year Country Recruitment years Tumor type Staining pattern Age(years) Gender Sample size(n) Detection method Cutoff Outcomes Survival mean (95% CI)/mean±SD months P value
P62 negative P62 positive
Kim HM 21 2017 Korea 2012-2013 Papillary thyroid carcinoma Whole cell NA NA 342 IHC (Abcam) >10% DFS 105 (101-109) 107 (104-110) 0.643
Kim HM 21 2017 Korea 2012-2013 Papillary thyroid carcinoma Whole cell NA NA 342 IHC (Abcam) >10% OS 108 (106-111) 106 (103-109) 0.14
Koo JS 22 2016 Korea 1997-2012 Lacrimal gland adenoid cystic carcinoma Whole cell 21-72 8/3 11 IHC (Abcam) Score≥2 DFS 45 (31-58) 18 (0-52) 0.1
Mohamed A 23 2015 USA 2000-2013 Gastric cancer Nucleus Median 64, range (53-84) 42/19 61 IHC (Abcam) >20% OS 2.60 ± 1.33 2.37 ± 0.19 0.48
Mohamed A 23 2015 USA 2000-2013 Gastric cancer Cytoplasm Median 64, range (53-84) 42/19 61 IHC (Abcam) >20% OS 2.46 ± 1.36 2.47 ± 1.10 0.97
Mohamed A 23 2015 USA 2000-2013 Colorectal cancer Nucleus Median 60.6, range (50-81) 28/17 45 IHC (Abcam) >20% OS 2.76 ± 1.71 2.45 ± 1.66 0.57
Mohamed A 23 2015 USA 2000-2013 Colorectal cancer Cytoplasm Median 60.6, range (50-81) 28/17 45 IHC (Abcam) >20% OS 2.63 ± 2.05 2.66 ± 1.59 0.97
Mohamed A 23 2015 USA 2000-2013 Pancreatic cancer Nucleus Median 64, range (50-75) 10/5 18 IHC (Abcam) >20% OS 1.34 ± 1.02 1.72 ± 1.04 0.55
Mohamed A 23 2015 USA 2000-2013 Pancreatic cancer Cytoplasm Median 64, range (50-75) 10/5 18 IHC (Abcam) >20% OS 1.77 ± 1.02 1.47 ± 1.06 0.56
Cha YJ 24 2014 Korea 2000-2012 Breast cancer Whole cell 63 (<50); 51(≥50) 0/114 114 IHC (Abcam) Score≥2 DFS 163 (156-169) 93 (89-89) 0.853
Cha YJ 24 2014 Korea 2000-2012 Breast cancer Whole cell 63 (<50); 51(≥50) 0/114 114 IHC (Abcam) Score≥2 OS 162 (155-169) 93 (89-97) 0.954
Kim JY 25 2014 Korea 2005-2012 Breast cancer Cytoplasm 34 (≤35); 300(>35) 0/334 334 IHC (Abcam) Score≥2 DFS 112 (99-125) 117 (111-124) 0.907
Kim JY 25 2014 Korea 2005-2012 Breast cancer Cytoplasm 34 (≤35); 300(>35) 0/334 334 IHC (Abcam) Score≥2 OS 117 (106-128) 126 (120-131) 0.289
Open in a new tab

NA, not acquired; M, male; F, female; n, number; IHC, immunohistochemistry; CI, confidence interval; SD, standard deviation; DFS, disease free survival; OS, overall survival.

P62 mRNA and protein expression profiles in various tumor tissues and normal tissues

The p62 mRNA and protein expression in different normal human tissues were generated according to the HPA. The p62 mRNA expressed in all normal tissues and the FPKM varied among different tissues (Fig. 2). Most normal tissues displayed moderate to strong cytoplasmic and nuclear p62 protein positivity, while cells in brain and cardiovascular system were weakly stained or negative (Fig. 2).

Figure 2.

Figure 2

Open in a new tab

The overview of p62 mRNA and protein expression in different normal human tissues. The data were generated in the Human Protein Atlas project (HPA). RNA-seq results generated in HPA are reported as Fragments per Kilo-base of exon per Million reads (FPKM). The score of protein expression describes the level of antibody staining observed in the annotated cell types as not detected (n), low (l), medium (m) or high (h). It is based on the staining intensity and fraction of stained cells. N/A not acquired.

According to the data generated in GEPIA, the expression of p62 mRNA was significantly higher in diffuse large B-cell lymphoma (DLBC), liver hepatocellular carcinoma (LIHC), pancreatic adenocarcinoma (PAAD), skin cutaneous melanoma (SKCM), and thymoma (THYM) than in their corresponding normal tissues (Fig. 3A-B). However, the p62 mRNA levels were lower in acute myeloid leukemia (LAML) in comparison with normal tissues (Fig. 3A-B).

Figure 3.

Figure 3

Open in a new tab

The p62 mRNA expression profile across all tumor samples and paired normal tissues. The data were generated in the Gene Expression Profiling Interactive Analysis project (GEPIA). The RNA-seq results are reported as number of transcripts per million (TPM). (A) Dot plot. Each dot represents expression of sample. (B) Bar plot. The height of bar represents the median expression of certain tumor type or normal tissue. ACC, Adrenocortical carcinoma; BLCA, Bladder Urothelial Carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, Cholangio carcinoma; COAD, Colon adenocarcinoma; DLBC, Lymphoid Neoplasm Diffuse Large B-cell Lymphoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and Neck squamous cell carcinoma; KICH, Kidney Chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LAML, Acute Myeloid Leukemia; LGG, Brain Lower Grade Glioma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma; MESO, Mesothelioma; OV, Ovarian serous cystadenocarcinoma; PAAD, Pancreatic adenocarcinoma; PCPG, Pheochromocytoma and Paraganglioma; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; SARC, Sarcoma; SKCM, Skin Cutaneous Melanoma; STAD, Stomach adenocarcinoma; TGCT, Testicular Germ Cell Tumors; THCA, Thyroid carcinoma; THYM, Thymoma; UCEC, Uterine Corpus Endometrial Carcinoma; UCS, Uterine Carcinosarcoma; UVM, Uveal Melanoma.

The differences of p62 protein expression in tumor tissues and normal tissues were also tested based on the literature review (Table 2). Among the 29 studies, twenty-five studies indicated that the expression of p62 protein was lower in normal tissues than in tumor tissues, which included breast cancer, colon adenocarcinoma, colorectal cancer, gastric cancer, melanoma, prostate cancer, oral squamous cell carcinomas, ovarian cancer, pancreatic cancer, head and neck carcinoma, glioblastoma and hepatocellular cancer (Table 2). Two authors thought p62 protein level was lower in the colorectal cancer and gastric cancer compared with corresponding normal tissues 17, 18. Another two authors thought there was no significant difference of p62 protein level between tumor tissues and normal tissues in prostate cancer and glioblastoma 19, 20.

Table 2.

Literature review on p62 expression in various normal tissues and tumor tissues.

Author Year Tumor type Detection method P62 protein abundance P value
N (n) T (n)
Xu LZ 35 2017 Breast WB (NA) Low (10) High (10) <0.01
Li SS 60 2017 Breast WB (Santa Cruz; CST) Low (5) High (5) <0.01
Kim SK 52 2013 Breast IHC (Abcam) Low (156) High (16) <0.05
Tang J 61 2012 Breast WB (Santa Cruz) Low (4) High (4) NA
Thompson HG 62 2003 Breast WB (Transduction Laboratories) Low (9) High (4) <0.05
Nakayama S 37 2017 Colorectal IHC (MBL) Low (28) High (118) 0.018
Niklaus M 38 2017 Colon IHC (LabForce) Low High <0.001
Schmitz KJ 41 2016 Colorectal IHC (Santa Cruz) Low (127) High (127) NA
Mohamed A 23 2015 Colon IHC (Abcam) Low (4) High (45) NA
Park JM 54 2013 Colorectal IHC (MBL) Low (171) High (171) NA
Chang LC 18 2013 Colorectal IHC (Abcam) High (83) Low (83) <0.05
Cao QH 17 2016 Gastric WB (MBL); IHC (MBL) High Low NA
Masuda GO 43 2016 Gastric IHC (MBL) Low High NA
Mohamed A 23 2015 Gastric IHC (Abcam) Low (6) High (61) NA
Tang DY 39 2016 Melanoma IHC (NA) Low High <0.01
Ellis RA 48 2014 Melanoma IHC (NA) 0.51% (29) 14.82% (121) <0.0001
Falasca L 63 2015 Prostate IHC (MBL) Low (12) High (26) <0.05
Jiang X 19 2015 Prostate IHC (MBL) Mainly in the nuclei Mainly in the cytoplasm No significance
Burdelski C 46 2015 Prostate IHC (Abcam) Low High NA
Giatromanolaki A 64 2014 Prostate IHC (Abcam) Low (NA) High (96) NA
Kitamura H 27 2006 Prostate IHC (Santa Cruz) Low and mainly in the nuclei (9) High and mainly in the cytoplasm (45) NA
Liu JL 26 2014 Oral IHC (Abcam) Mainly in the nuclei Mainly in the cytoplasm <0.001
Inui T 51 2013 Oral IHC (MBL) Low (14) High (54) <0.0001
Ju LL 28 2016 Ovarian IHC (NA) Low (13) High (47) <0.05
Mohamed A 23 2015 Pancreatic IHC (Abcam) Low (4) High (18) NA
Kuo WL 65 2014 Head and neck IHC (MBL) Low (76) High (199) <0.01
Okada M 20 2014 Ameloblastoma IHC (MBL) Positive rate 67% (9) Positive rate 69% (49) No significance
Giatromanolaki A 66 2014 Glioblastoma IHC (Abcam); WB (Abcam) Low High NA
Jin GZ 50 2013 Hepatocellular IHC (Sigma) Low (46) High (51) <0.0001
Open in a new tab

NA, not acquired; N, normal tissues; T, tumor tissues; n, number; IHC, immunohistochemistry; WB, western blot

Association between p62 expression and overall survival (OS)

Twenty-two articles included 12,813 patients were collected to evaluate the relationship between p62 expression and OS. The random-effects model was employed because obvious heterogeneity was found in the meta-analysis (I2 = 79.9%, P < 0.01). The pooled HR revealed that p62 over-expression was associated with a worse prognosis compared with the low expression group (HR 1.50, 95% CI: 1.17-1.93, P < 0.05) (Fig. 4A).

Figure 4.

Figure 4

Open in a new tab

Forest plots of studies evaluating the effect of p62 overexpression on overall survival (OS). (A) P62 overexpression was associated with worse OS in malignant tumors; Subgroup analyses investigating the relationship between p62 overexpression and OS according to (B) tumor stage, (C) staining pattern and (D) tumor type.

Given the significant heterogeneity in the meta-analysis involving all 20 studies, we performed a series of subgroup analyses to estimate the possible correlation between p62 expression and OS based on three main features, including tumor stage, staining pattern, and tumor type. The first subgroup analysis was evaluated according to tumor stage. We observed that p62 over-expression in early stage tumor was related to worse OS (HR 1.85, 95% CI: 1.24-2.76, P < 0.01) with no heterogeneity in the data (I2 = 0.0%, P = 0.668). As for late stage subgroup, there was only one study indicating no association between p62 expression and OS in colorectal cancer (Fig. 4B). Subgroup analysis based on staining pattern showed that high p62 expression in cytoplasm was associated with poor OS (HR 1.53, 95% CI: 1.03-2.27, P < 0.05) whereas p62 over-expression in nucleus was not statistically associated with OS (HR 0.98, 95% CI: 0.49-1.97, P = 0.965) (Fig. 4C). In the subgroup analysis of OS by tumor type, we found that high p62 level was associated with poor OS of patients with nasopharyngeal cancer (HR 3.92, 95% CI: 1.74-8.82, P < 0.01), non-small cell lung cancer (HR 2.93, 95% CI: 1.30-6.59, P < 0.01), prostate cancer (HR 1.62, 95% CI: 1.33-1.97, P < 0.01), glioma (HR 2.32, 95% CI: 1.03-5.20, P < 0.05), oral squamous cell carcinoma (HR 1.76, 95% CI: 1.17-2.63, P < 0.01), and epithelial ovarian cancer (HR 2.33, 95% CI: 1.43-3.79, P < 0.01) (Fig. 4D). In esophageal cancer, high p62 level indicated a better OS (HR 0.55, 95% CI: 0.33-0.91, P < 0.05) with only one study included. In other types of cancer such as colorectal cancer, gastric cancer, endometrial cancer, melanoma and breast cancer, p62 expression was not associated with the OS (Fig. 4D). The separate articles reporting mean survival time indicated that p62 expression had no effect on the OS in papillary thyroid carcinoma, gastric cancer, colorectal cancer, pancreatic cancer, and breast cancer (Table 3).

Association between p62 expression and disease-free survival (DFS)

In our analysis, we merged DFS, RFS, MFS and PFS together considering the similarities among them. The effect of p62 expression on DFS was evaluated in 14 studies with 3,212 patients. A random-effect model was used to calculate the pooled HRs and 95% CIs due to the significant heterogeneity among studies (I2 = 67.6%, P<0.01). The pooled results showed that p62 over-expression was associated with poor DFS in patients (HR 1.38, 95% CI: 1.06-1.79, P<0.05) (Fig. 5A).

Figure 5.

Figure 5

Open in a new tab

Forest plots of studies evaluating the effect of p62 overexpression on disease-free survival (DFS). (A) P62 overexpression was associated with worse DFS in malignant tumors; Subgroup analyses investigating the relationship between p62 overexpression and DFS according to (B) tumor stage, (C) staining pattern and (D) tumor type.

Given the significant heterogeneity in the meta-analysis involving all 14 studies, we performed a series of subgroup analyses to estimate the possible correlation between p62 expression and DFS based on tumor stage, staining pattern, and tumor type. In the subgroup analysis according to tumor stage, we found that in early stage group, p62 over-expression was related to worse DFS (HR 1.48, 95% CI: 1.11-1.95, P < 0.01) with slight heterogeneity in the pooled data (I2 = 5.5%, P = 0.375) (Fig. 5B). As for late stage group, there was only one eligible study indicating that p62 over-expression was associated poor DFS in hypopharyngeal squamous cell carcinomas (Fig. 5B). In the subgroup analysis of DFS by staining pattern, we found that neither p62 overexpression in cytoplasm (HR 0.84, 95% CI: 0.42-1.67, P = 0.618) nor in nucleus (HR 0.73, 95% CI: 0.36-1.44, P = 0.360) was related to the DFS with significant heterogeneity appearing (Fig. 5C). In the subgroup analysis of DFS by tumor type, an increased p62 expression in tumor was associated with worse DFS of patients with nasopharyngeal cancer (HR 2.87, 95% CI: 1.16-7.12, P < 0.05), hypopharyngeal cancer (HR 2.76, 95% CI: 1.05-7.25, P < 0.05), non-small cell lung cancer (HR 1.66, 95% CI: 1.12-2.45, P < 0.05) and glioma (HR 2.69, 95% CI: 1.14-6.31, P < 0.05) (Fig. 5D). However, in other types of cancer such as breast cancer, hepatocellular carcinoma, melanoma and oral squamous cell carcinoma, there was no significant relationship between p62 expression and DFS statistically (Fig. 5D). In addition, four articles listed in the Table 3 reported that p62 expression was not associated with DFS in papillary thyroid carcinoma, lacrimal gland adenoid cystic carcinoma and breast cancer (Table 3).

Association between p62 expression and disease-specific survival (DSS)

DSS was reported in 8 articles covering 1,379 patients. A low heterogeneity (I2 = 30.6%, P = 0.16) was observed among these studies, so a fixed-effect model was utilized to analyze. The pooled HR for articles assessing the effect of p62 overexpression on DSS was 1.41 (95% CI: 1.16-1.73, P < 0.01) (Fig. 6A).

Figure 6.

Figure 6

Open in a new tab

Forest plots of studies evaluating the effect of p62 overexpression on disease-specific survival (DSS). (A) P62 overexpression was associated with worse DSS in malignant tumors; Subgroup analyses investigating the relationship between p62 overexpression and DSS according to (B) staining pattern and (C) tumor type.

Subgroup analyses by staining pattern and tumor type were also performed to further explore the possible correlation between p62 expression and DSS in patients with different clinicopathologic features. According to the staining pattern, we observed that high lever p62 in cytoplasm was related to worse DSS (HR 1.60, 95% CI: 1.15-2.24, P < 0.01) with no heterogeneity in the pooled data (I2 = 0.0%, P = 0.621) (Fig. 6B). However, p62 high expression in nucleus was not related to DSS with significant heterogeneity appearing (I2 = 88.2%, P = 0.004) (Fig. 6 B). In the subgroup analysis based on tumor type, pooled results indicated that high p62 level was associated with poor DSS of patients with oral squamous cell carcinoma (HR 2.09, 95% CI: 1.42-3.07, P < 0.01) and non-small cell lung cancer (HR 2.00, 95% CI: 1.08-3.72, P < 0.05) (Fig. 6C). In other types of cancer such as colorectal cancer, melanoma, soft tissue sarcoma and breast cancer, p62 expression was not associated with the DSS significantly (Fig. 6C).

Sensitivity analysis and publication bias

Sensitivity analysis was performed to validate the influences of each study on the pooled results of OS, DFS and DSS by omitting each single study sequentially. The results indicated that the synthetic estimates of the effect of p62 overexpression on OS, DFS and DSS did not vary significantly with the omission of any individual study, which meant that the results of this meta-analysis were robust after using the leave-one-out method.

Begg's funnel plot and Egger's test were used to assess the publication bias of these applicable studies. The shapes of funnel plots for OS, DFS, and DSS showed no evidences of obvious asymmetry (Fig. 7A-C). The P-values of Begg's and Egger's tests were all over 0.05 (OS, P = 0.413 for the Begg's test, P = 0.368 for the Egger's test; DFS, P = 0.488 for the Begg's test, P = 0.143 for the Egger's test; DSS, P = 0.283 for the Begg's test, P = 0.728 for the Egger's test). The above results indicated that there was no significant publication bias existing in this meta-analysis.

Figure 7.

Figure 7

Open in a new tab

Begg's funnel plots for assessing potential publication bias. (A) Funnel plot analysis for overall survival (OS); (B) Funnel plot analysis for disease-free survival (DFS); (C) Funnel plot analysis for disease-specific survival (DSS).

P62 mRNA expression in tumors and patients' survival

Based on the data from TCGA and HPA, we assessed the association between p62 mRNA expression and OS in various tumors using Kaplan-Meier survival plots (Fig. 8). The association between p62 mRNA expression and OS in various malignant tumors was summarized in Table 4. By generating the median and maximally separated Kaplan-Meier plots, we found that the high p62 mRNA expression group had significant worse OS only in the liver cancer analyzed with maximally separated Kaplan-Meier plots (Fig. 8). In other tumors, p62 mRNA level was not associated with the patients' survival (Table 4).

Figure 8.

Figure 8

Open in a new tab

Survival analysis of p62 mRNA expression according to the TCGA and HPA databases. (A) Liver cancer, (B) Lung cancer, (C) Breast cancer, (D) Cervical cancer, (E) Ovarian cancer, (F) Endometrial cancer. Purple lines represent high expression of p62 and blue lines represent low expression.

Table 4.

Association between p62 mRNA level and OS based on the TCGA and HPA databases

Tumor type Best separation Median separation
Cutoff (FPKM) P value Cutoff (FPKM) P value
Liver cancer 110.7 2.31E-05 66.4 4.09E-02
Lung cancer 38.7 1.34E-01 38.6 1.44E-01
Breast cancer 46.5 1.08E-01 33.9 7.71E-01
Cervical cancer 36.4 1.39E-01 28.4 9.65E-01
Ovarian cancer 22.8 5.65E-02 34.6 8.04E-01
Endometrial cancer 24.6 9.45E-02 26.8 4.69E-01
Glioma 26.2 1.21E-02 28.0 4.42E-02
Thyroid cancer 70.3 4.41E-02 60.4 5.27E-01
Urothelial cancer 22.0 2.01E-01 28.7 9.85E-01
Renal cancer 58.1 9.52E-02 40.1 8.98E-01
Prostate cancer 24.6 1.70E-01 29.4 4.24E-01
Testis cancer 16.6 8.68E-03 12.3 2.02E-02
Stomach cancer 24.3 3.21E-01 32.8 5.59E-01
Colorectal cancer 49.2 3.19E-01 38.7 4.88E-01
Pancreatic cancer 41.6 1.66E-01 38.8 3.80E-01
Head and neck cancer 38.1 1.08E-01 26.7 2.00E-01
Melanoma 40.6 2.34E-01 51.5 6.22E-01
Open in a new tab

FPKM, Fragments per Kilo-base of exon per Million reads

Discussion

The expression of p62 mRNA and protein varied in different tissues, and in generally, the expression level of p62 protein was higher in malignant tumor tissues in comparison with normal tissues. This study analyzed the expression of p62 on the protein and mRNA levels in various types of tumors and evaluated its prognostic value. Furthermore, we performed subgroup analysis to explore the possible association between p62 expression and survival in tumor patients with different clinicopathologic features. A total of 14,072 tumor patients from 30 individual articles were enrolled in this study and the synthetic results indicated that p62 overexpression significantly predicted worse OS, DFS, and DSS in various tumors as a whole. Furthermore, subgroup analysis showed that the impact of p62 expression on tumor prognosis varied according to the differences in tumor stage, tumor type and p62 location. The adverse effect of p62 overexpression on OS, DFS and DSS was more certain in early stage than that in late stage. P62 accumulation in cytoplasm was associated with worse OS and DSS in various cancers whereas nuclear p62 was less effective. In the subgroup analysis by tumor type, we revealed that p62 overexpression was generally associated with worse survival in certain tumors such as non-small cell lung cancer, nasopharyngeal cancer, oral squamous cell carcinoma, glioma, prostate cancer, epithelial ovarian cancer, hypopharyngeal cancer, and melanoma. There were also 5 articles reporting that p62 expression had not impact on corresponding cancer prognosis separately 21-25. Considering their small sample size and different presentation style, their results were not synthesized into the meta-analysis.

Recent studies reported that the p62 protein in benign tissues was mainly distributed in nuclei while p62 in tumor tissues was distributed obviously in cytoplasm 19, 26, 27. Our pooled results showed that the cytoplasmic p62 accumulation predicted a worse prognosis in malignant tumors, and it was evident in the early stage tumors. However, nuclear p62 accumulation and p62 mRNA overexpression had no such effect statistically. Nuclear p62 protein and p62 mRNA might indicate the generation of p62, whereas the cytoplasm p62 depends on the dynamic balance between generation and degradation. The degradation of p62 along with other autophagosomal contents is a critical process during autophagy 2. Therefore, accumulation of p62 reflects impaired autophagy, a process reported to be a key to the onset of tumorigenesis 7. In contrast to the p62 generation, the degradation of p62 might have more important impact on the tumor survival. Consistent with the anti-tumor role of autophagy in early stage, it is reasonable that in early stage cytoplasmic p62 accumulation is associated with worse survival. Given the dual role of autophagy in tumorigenesis and progression, the autophagy related protein should be considered as a potential prognostic biomarker or therapeutic target according to the characteristics of tumor. Apart from the direct survival analysis, p62 expression was reported to be associated with lymph node status, distant metastasis, disease relapse and drug resistance 20, 28, 29. High level of p62 also allowed cancer cells evade apoptosis and promote cancer progression through activating NF-κB and Nrf2 signaling pathways 30, 31. P62 might participate in the regulation of tumor progression through multiple physiological processes in addition to autophagy pathway.

A recent study from Ruan et al. 32 which was published in Oncotarget, also examined the relationship between p62 expression and survival outcomes in solid tumor patients by combining 20 studies. However, there were another 15 published articles being suitable for this meta-analysis but not enrolled in their study. Our study updated the data to provide more accurate estimates with a stronger statistical power. Furthermore, we performed the subgroup analyses by tumor stage, p62 staining pattern and tumor type and found the strength of association between p62 and prognosis varied according to different clinicopathologic features. We also tested the predictive role of p62 mRNA level on patients' survival in various types of tumors.

Despite our efforts to conduct a comprehensive analysis, several limitations remain to be recognized. First, the synthetic results are inevitably compromised by the potential publication bias because this meta-analysis is based on the reported studies. Predominantly positive results are more liable to be published and inflate our estimate for the association between p62 and patients' survival. Second, all the included studies in our analysis are cohort studies and the cutoff values varied in different studies, which may influence the validity of p62 as a predictive biomarker in tumor prognosis. Third, certain HRs and 95% CIs were calculated from the Kaplan-Meier curves, so this might bring statistical deviations inevitably. Finally, there was significant heterogeneity in patient populations, clinical therapeutic methods and follow-up time. Although random-effects model and sensitivity analysis were carried out to address this heterogeneity, these statistical methods might not be sufficient.

Conclusions

The pooled results of the meta-analysis suggest that p62 overexpression was associated with worse prognosis in certain types of tumors. Further subgroup analyses indicate that cytoplasmic p62 accumulation can be a prognostic marker for early stage tumors. Considering the limitations of this meta-analysis, this conclusion should be regarded with caution. Further well-designed studies with larger sample size are needed to verify the role of p62 expression on tumor prognosis.

Acknowledgments

This study was supported by the National Key Research and Development Program of China (Project 2017YFC0113500), the Major Scientific and Technological Development Program of Zhejiang Province (Project 2014C03032), The Traditional Chinese Medical Science and Technology Key Research plan of Zhejiang Province (Project 2015ZZ007) and "The 13th five year" Traditional Chinese Medicine (integrated Chinese traditional and Western medicine) Key Discipline of Zhejiang Province (Innovative lung cancer diagnosis and treatment with combination of Chinese traditional and Western medicine 2017-XK-A33). We also acknowledge the efforts of the TCGA and HPA staffs in the creation of the TCGA and HPA databases.

References

  • 1.Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015;65:87–108. doi: 10.3322/caac.21262. [DOI] [PubMed] [Google Scholar]
  • 2.Kundu M, Thompson CB. Autophagy: basic principles and relevance to disease. Annual review of pathology. 2008;3:427–55. doi: 10.1146/annurev.pathmechdis.2.010506.091842. [DOI] [PubMed] [Google Scholar]
  • 3.Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132:27–42. doi: 10.1016/j.cell.2007.12.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. 2008;451:1069–75. doi: 10.1038/nature06639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. The New England journal of medicine. 2013;368:651–62. doi: 10.1056/NEJMra1205406. [DOI] [PubMed] [Google Scholar]
  • 6.Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science (New York, NY) 2004;306:990–5. doi: 10.1126/science.1099993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F. et al. Autophagy in malignant transformation and cancer progression. The EMBO journal. 2015;34:856–80. doi: 10.15252/embj.201490784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Moscat J, Diaz-Meco MT. p62: a versatile multitasker takes on cancer. Trends in biochemical sciences. 2012;37:230–6. doi: 10.1016/j.tibs.2012.02.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Jiang P, Mizushima N. LC3- and p62-based biochemical methods for the analysis of autophagy progression in mammalian cells. Methods (San Diego, Calif) 2015;75:13–8. doi: 10.1016/j.ymeth.2014.11.021. [DOI] [PubMed] [Google Scholar]
  • 10.Rogov V, Dotsch V, Johansen T, Kirkin V. Interactions between autophagy receptors and ubiquitin-like proteins form the molecular basis for selective autophagy. Molecular cell. 2014;53:167–78. doi: 10.1016/j.molcel.2013.12.014. [DOI] [PubMed] [Google Scholar]
  • 11.Puissant A, Fenouille N, Auberger P. When autophagy meets cancer through p62/SQSTM1. Am J Cancer Res. 2012;2:397–413. [PMC free article] [PubMed] [Google Scholar]
  • 12.Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A. et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) Autophagy. 2016;12:1–222. doi: 10.1080/15548627.2015.1100356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine. 2009;6:e1000097. doi: 10.1371/journal.pmed.1000097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Wang Y, Zeng T. Response to: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2013;14:391. doi: 10.1186/1745-6215-14-391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology. 2010;25:603–5. doi: 10.1007/s10654-010-9491-z. [DOI] [PubMed] [Google Scholar]
  • 16.Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed) 2003;327:557–60. doi: 10.1136/bmj.327.7414.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Cao QH, Liu F, Yang ZL, Fu XH, Yang ZH, Liu Q. et al. Prognostic value of autophagy related proteins ULK1, Beclin 1, ATG3, ATG5, ATG7, ATG9, ATG10, ATG12, LC3B and p62/SQSTM1 in gastric cancer. American journal of translational research. 2016;8:3831–47. [PMC free article] [PubMed] [Google Scholar]
  • 18.Chang LC, Fan CW, Tseng WK, Chen JR, Chein HP, Hwang CC. et al. Immunohistochemical study of the Nrf2 pathway in colorectal cancer: Nrf2 expression is closely correlated to Keap1 in the tumor and Bach1 in the normal tissue. Applied immunohistochemistry & molecular morphology: AIMM. 2013;21:511–7. doi: 10.1097/PAI.0b013e318282ac20. [DOI] [PubMed] [Google Scholar]
  • 19.Jiang X, Zhong W, Huang H, He H, Jiang F, Chen Y. et al. Autophagy defects suggested by low levels of autophagy activator MAP1S and high levels of autophagy inhibitor LRPPRC predict poor prognosis of prostate cancer patients. Molecular carcinogenesis. 2015;54:1194–204. doi: 10.1002/mc.22193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Okada M, Oikawa M, Miki Y, Shimizu Y, Echigo S, Takahashi T. et al. Immunohistochemical assessment of ATG7, LC3, and p62 in ameloblastomas. Journal of oral pathology & medicine: official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2014;43:606–12. doi: 10.1111/jop.12177. [DOI] [PubMed] [Google Scholar]
  • 21.Kim HM, Kim ES, Koo JS. Expression of Autophagy-Related Proteins in Different Types of Thyroid Cancer. Int J Mol Sci; 2017. p. 18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Koo JS, Kim JW, Yoon JS. Expression of Autophagy and Reactive Oxygen Species-Related Proteins in Lacrimal Gland Adenoid Cystic Carcinoma. Yonsei medical journal. 2016;57:482–9. doi: 10.3349/ymj.2016.57.2.482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Mohamed A, Ayman A, Deniece J, Wang T, Kovach C, Siddiqui MT. et al. P62/Ubiquitin IHC Expression Correlated with Clinicopathologic Parameters and Outcome in Gastrointestinal Carcinomas. Front Oncol. 2015;5:70. doi: 10.3389/fonc.2015.00070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Cha YJ, Kim YH, Cho NH, Koo JS. Expression of autophagy related proteins in invasive lobular carcinoma: comparison to invasive ductal carcinoma. International journal of clinical and experimental pathology. 2014;7:3389–98. [PMC free article] [PubMed] [Google Scholar]
  • 25.Kim JY, Jung WH, Koo JS. Expression of autophagy-related proteins according to androgen receptor and HER-2 status in estrogen receptor-negative breast cancer. PLoS One. 2014;9:e105666. doi: 10.1371/journal.pone.0105666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Liu JL, Chen FF, Lung J, Lo CH, Lee FH, Lu YC. et al. Prognostic significance of p62/SQSTM1 subcellular localization and LC3B in oral squamous cell carcinoma. British journal of cancer. 2014;111:944–54. doi: 10.1038/bjc.2014.355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Kitamura H, Torigoe T, Asanuma H, Hisasue SI, Suzuki K, Tsukamoto T. et al. Cytosolic overexpression of p62 sequestosome 1 in neoplastic prostate tissue. Histopathology. 2006;48:157–61. doi: 10.1111/j.1365-2559.2005.02313.x. [DOI] [PubMed] [Google Scholar]
  • 28.Ju LL, Zhao CY, Ye KF, Yang H, Zhang J. Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues. European review for medical and pharmacological sciences. 2016;20:1993–2003. [PubMed] [Google Scholar]
  • 29.Rich T, Dean RT, Lamm CG, Ramiro-Ibanez F, Stevenson ML, Patterson-Kane JC. p62/Sequestosome-1: Mapping Sites of Protein-Handling Stress in Canine Cutaneous Mast Cell Tumors. Veterinary pathology. 2015;52:621–30. doi: 10.1177/0300985814548489. [DOI] [PubMed] [Google Scholar]
  • 30.Shi J, Wong J, Piesik P, Fung G, Zhang J, Jagdeo J. et al. Cleavage of sequestosome 1/p62 by an enteroviral protease results in disrupted selective autophagy and impaired NFKB signaling. Autophagy. 2013;9:1591–603. doi: 10.4161/auto.26059. [DOI] [PubMed] [Google Scholar]
  • 31.Inami Y, Waguri S, Sakamoto A, Kouno T, Nakada K, Hino O. et al. Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. The Journal of cell biology. 2011;193:275–84. doi: 10.1083/jcb.201102031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Ruan H, Xu J, Wang L, Zhao Z, Kong L, Lan B. et al. The prognostic value of p62 in solid tumor patients: a meta-analysis. Oncotarget. 2018;9:4258–66. doi: 10.18632/oncotarget.23101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Yang Q, Zhang MX, Zou X, Liu YP, You R, Yu T. et al. A Prognostic Bio-Model Based on SQSTM1 and N-Stage Identifies Nasopharyngeal Carcinoma Patients at High Risk of Metastasis for Additional Induction Chemotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2018;24:648–58. doi: 10.1158/1078-0432.CCR-17-1963. [DOI] [PubMed] [Google Scholar]
  • 34.Terabe T, Uchida F, Nagai H, Omori S, Ishibashi-Kanno N, Hasegawa S. et al. Expression of autophagy-related markers at the surgical margin of oral squamous cell carcinoma correlates with poor prognosis and tumor recurrence. Hum Pathol. 2018;73:156–63. doi: 10.1016/j.humpath.2017.11.019. [DOI] [PubMed] [Google Scholar]
  • 35.Xu LZ, Li SS, Zhou W, Kang ZJ, Zhang QX, Kamran M. et al. p62/SQSTM1 enhances breast cancer stem-like properties by stabilizing MYC mRNA. Oncogene. 2017;36:304–17. doi: 10.1038/onc.2016.202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Arai A, Chano T, Ikebuchi K, Hama Y, Ochi Y, Tameno H. et al. p62/SQSTM1 levels predicts radiotherapy resistance in hypopharyngeal carcinomas. Am J Cancer Res. 2017;7:881–91. [PMC free article] [PubMed] [Google Scholar]
  • 37.Nakayama S, Karasawa H, Suzuki T, Yabuuchi S, Takagi K, Aizawa T. et al. p62/sequestosome 1 in human colorectal carcinoma as a potent prognostic predictor associated with cell proliferation. Cancer Med. 2017;6:1264–74. doi: 10.1002/cam4.1093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Niklaus M, Adams O, Berezowska S, Zlobec I, Graber F, Slotta-Huspenina J. et al. Expression analysis of LC3B and p62 indicates intact activated autophagy is associated with an unfavorable prognosis in colon cancer. Oncotarget. 2017;8:54604–15. doi: 10.18632/oncotarget.17554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Tang DY, Ellis RA, Lovat PE. Prognostic Impact of Autophagy Biomarkers for Cutaneous Melanoma. Front Oncol. 2016;6:236. doi: 10.3389/fonc.2016.00236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Schlafli AM, Adams O, Galvan JA, Gugger M, Savic S, Bubendorf L. et al. Prognostic value of the autophagy markers LC3 and p62/SQSTM1 in early-stage non-small cell lung cancer. Oncotarget. 2016;7:39544–55. doi: 10.18632/oncotarget.9647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Schmitz KJ, Ademi C, Bertram S, Schmid KW, Baba HA. Prognostic relevance of autophagy-related markers LC3, p62/sequestosome 1, Beclin-1 and ULK1 in colorectal cancer patients with respect to KRAS mutational status. World journal of surgical oncology. 2016;14:189. doi: 10.1186/s12957-016-0946-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Adams O, Dislich B, Berezowska S, Schlafli AM, Seiler CA, Kroll D. et al. Prognostic relevance of autophagy markers LC3B and p62 in esophageal adenocarcinomas. Oncotarget. 2016;7:39241–55. doi: 10.18632/oncotarget.9649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Masuda GO, Yashiro M, Kitayama K, Miki Y, Kasashima H, Kinoshita H. et al. Clinicopathological Correlations of Autophagy-related Proteins LC3, Beclin 1 and p62 in Gastric Cancer. Anticancer Res. 2016;36:129–36. [PubMed] [Google Scholar]
  • 44.Iwadate R, Inoue J, Tsuda H, Takano M, Furuya K, Hirasawa A. et al. High Expression of p62 Protein Is Associated with Poor Prognosis and Aggressive Phenotypes in Endometrial Cancer. The American journal of pathology. 2015;185:2523–33. doi: 10.1016/j.ajpath.2015.05.008. [DOI] [PubMed] [Google Scholar]
  • 45.Wang X, Du Z, Li L, Shi M, Yu Y. Beclin 1 and p62 expression in non-small cell lung cancer: relation with malignant behaviors and clinical outcome. International journal of clinical and experimental pathology. 2015;8:10644–52. [PMC free article] [PubMed] [Google Scholar]
  • 46.Burdelski C, Reiswich V, Hube-Magg C, Kluth M, Minner S, Koop C. et al. Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2015;21:3471–9. doi: 10.1158/1078-0432.CCR-14-0620. [DOI] [PubMed] [Google Scholar]
  • 47.Zhao M, Xu H, Zhang B, Hong B, Yan W, Zhang J. Impact of nuclear factor erythroid-derived 2-like 2 and p62/sequestosome expression on prognosis of patients with gliomas. Hum Pathol. 2015;46:843–9. doi: 10.1016/j.humpath.2015.02.009. [DOI] [PubMed] [Google Scholar]
  • 48.Ellis RA, Horswell S, Ness T, Lumsdon J, Tooze SA, Kirkham N. et al. Prognostic impact of p62 expression in cutaneous malignant melanoma. The Journal of investigative dermatology. 2014;134:1476–8. doi: 10.1038/jid.2013.497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Iwadate R, Inoue J, Tsuda H, Takano M, Furuya K, Hirasawa A. et al. High Expression of SQSTM1/p62 Protein Is Associated with Poor Prognosis in Epithelial Ovarian Cancer. Acta histochemica et cytochemica. 2014;47:295–301. doi: 10.1267/ahc.14048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Jin GZ, Dong H, Yu WL, Li Y, Lu XY, Yu H. et al. A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values. BMC Cancer. 2013;13:161. doi: 10.1186/1471-2407-13-161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Inui T, Chano T, Takikita-Suzuki M, Nishikawa M, Yamamoto G, Okabe H. Association of p62/SQSTM1 excess and oral carcinogenesis. PLoS One. 2013;8:e74398. doi: 10.1371/journal.pone.0074398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Kim SK, Jung WH, Koo JS. Expression of autophagy-related proteins in phyllodes tumor. International journal of clinical and experimental pathology. 2013;6:2145–56. [PMC free article] [PubMed] [Google Scholar]
  • 53.Luo RZ, Yuan ZY, Li M, Xi SY, Fu J, He J. Accumulation of p62 is associated with poor prognosis in patients with triple-negative breast cancer. OncoTargets and therapy. 2013;6:883–8. doi: 10.2147/OTT.S46222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Park JM, Huang S, Wu TT, Foster NR, Sinicrope FA. Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy. Cancer biology & therapy. 2013;14:100–7. doi: 10.4161/cbt.22954. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Choi J, Jung W, Koo JS. Expression of autophagy-related markers beclin-1, light chain 3A, light chain 3B and p62 according to the molecular subtype of breast cancer. Histopathology. 2013;62:275–86. doi: 10.1111/his.12002. [DOI] [PubMed] [Google Scholar]
  • 56.Sorbye SW, Kilvaer TK, Valkov A, Donnem T, Smeland E, Al-Shibli K. et al. Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas. PLoS One. 2012;7:e47068. doi: 10.1371/journal.pone.0047068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Inoue D, Suzuki T, Mitsuishi Y, Miki Y, Suzuki S, Sugawara S. et al. Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Sci. 2012;103:760–6. doi: 10.1111/j.1349-7006.2012.02216.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Kim S, Jung WH, Koo JS. Differences in autophagy-related activity by molecular subtype in triple-negative breast cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2012;33:1681–94. doi: 10.1007/s13277-012-0424-1. [DOI] [PubMed] [Google Scholar]
  • 59.Rolland P, Madjd Z, Durrant L, Ellis IO, Layfield R, Spendlove I. The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Endocrine-related cancer. 2007;14:73–80. doi: 10.1677/erc.1.01312. [DOI] [PubMed] [Google Scholar]
  • 60.Li SS, Xu LZ, Zhou W, Yao S, Wang CL, Xia JL. et al. p62/SQSTM1 interacts with vimentin to enhance breast cancer metastasis. Carcinogenesis. 2017;38:1092–103. doi: 10.1093/carcin/bgx099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Tang J, Deng R, Luo RZ, Shen GP, Cai MY, Du ZM. et al. Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients. Breast cancer research and treatment. 2012;134:549–60. doi: 10.1007/s10549-012-2080-y. [DOI] [PubMed] [Google Scholar]
  • 62.Thompson HG, Harris JW, Wold BJ, Lin F, Brody JP. p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells. Oncogene. 2003;22:2322–33. doi: 10.1038/sj.onc.1206325. [DOI] [PubMed] [Google Scholar]
  • 63.Falasca L, Torino F, Marconi M, Costantini M, Pompeo V, Sentinelli S. et al. AMBRA1 and SQSTM1 expression pattern in prostate cancer. Apoptosis: an international journal on programmed cell death. 2015;20:1577–86. doi: 10.1007/s10495-015-1176-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Giatromanolaki A, Sivridis E, Mendrinos S, Koutsopoulos AV, Koukourakis MI. Autophagy proteins in prostate cancer: relation with anaerobic metabolism and Gleason score. Urologic oncology. 2014;32(39 e):11–8. doi: 10.1016/j.urolonc.2013.04.003. [DOI] [PubMed] [Google Scholar]
  • 65.Kuo WL, Sharifi MN, Lingen MW, Ahmed O, Liu J, Nagilla M. et al. p62/SQSTM1 accumulation in squamous cell carcinoma of head and neck predicts sensitivity to phosphatidylinositol 3-kinase pathway inhibitors. PLoS One. 2014;9:e90171. doi: 10.1371/journal.pone.0090171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Giatromanolaki A, Sivridis E, Mitrakas A, Kalamida D, Zois CE, Haider S. et al. Autophagy and lysosomal related protein expression patterns in human glioblastoma. Cancer biology & therapy. 2014;15:1468–78. doi: 10.4161/15384047.2014.955719. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Cancer are provided here courtesy of Ivyspring International Publisher

RESOURCES